Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102), and Oxaliplatin (iTTo) for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04808791 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT04808791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04808791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102), and Oxaliplatin (iTTo) for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Completed
Start date
October 27, 2021
Completion date
July 21, 2023
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric carcinoma, gastroesophageal junction adenocarcinoma